Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation

Mark A. Schnitzler, Karen E. Craig, Karen E. Hardinger, Jeffrey A. Lowell, Daniel Brennan

Research output: Contribution to journalArticle

Abstract

Background. A previous study has argued that mycophenolate mofetil (MMF) is associated with a reduced incidence of death with function when compared to azathioprine (AZA) in cadaveric renal transplantation. This study was designed to verify this result because methodological issues bring these findings into question. Methods. The data used in this study was derived from records of renal transplants performed in 1995 and 1996 as recorded in the UNOS Scientific Renal Transplant Registry and supplied by the United States Renal Data System (USRDS). Univariate and multivariate survival analysis was used to compare rates of death with function. Covariate characteristics of the donor, recipient, procedures, early outcomes and the transplant centre were considered. Results. 12 251 recipients of cadaveric renal transplants were identified as having received either MMF or AZA, but not both. The relative risk of death with function calculated by the Kaplan-Meier method was 21% less for MMF patients (P = 0.005). MMF had from 21% (P = 0.008) to 24% (P = 0.001) reductions in relative risk by multivariate methods. Conclusions. The use of MMF is associated with a reduction in the incidence of death with a functioning graft in cadaveric renal transplantation. These results verify previous analyses.

Original languageEnglish (US)
Pages (from-to)1197-1200
Number of pages4
JournalNephrology Dialysis Transplantation
Volume18
Issue number6
DOIs
StatePublished - Jun 1 2003
Externally publishedYes

Fingerprint

Mycophenolic Acid
Azathioprine
Kidney Transplantation
Transplants
Kidney
Incidence
Survival Analysis
Information Systems
Registries
Multivariate Analysis
Tissue Donors
Mortality

Keywords

  • Azathioprine
  • Cadaveric renal transplantation
  • Death with function
  • Immunosuppression
  • Mycophenolate mofetil

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation. / Schnitzler, Mark A.; Craig, Karen E.; Hardinger, Karen E.; Lowell, Jeffrey A.; Brennan, Daniel.

In: Nephrology Dialysis Transplantation, Vol. 18, No. 6, 01.06.2003, p. 1197-1200.

Research output: Contribution to journalArticle

Schnitzler, Mark A. ; Craig, Karen E. ; Hardinger, Karen E. ; Lowell, Jeffrey A. ; Brennan, Daniel. / Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation. In: Nephrology Dialysis Transplantation. 2003 ; Vol. 18, No. 6. pp. 1197-1200.
@article{de8bc958efc84642b76e91044a62f4c6,
title = "Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation",
abstract = "Background. A previous study has argued that mycophenolate mofetil (MMF) is associated with a reduced incidence of death with function when compared to azathioprine (AZA) in cadaveric renal transplantation. This study was designed to verify this result because methodological issues bring these findings into question. Methods. The data used in this study was derived from records of renal transplants performed in 1995 and 1996 as recorded in the UNOS Scientific Renal Transplant Registry and supplied by the United States Renal Data System (USRDS). Univariate and multivariate survival analysis was used to compare rates of death with function. Covariate characteristics of the donor, recipient, procedures, early outcomes and the transplant centre were considered. Results. 12 251 recipients of cadaveric renal transplants were identified as having received either MMF or AZA, but not both. The relative risk of death with function calculated by the Kaplan-Meier method was 21{\%} less for MMF patients (P = 0.005). MMF had from 21{\%} (P = 0.008) to 24{\%} (P = 0.001) reductions in relative risk by multivariate methods. Conclusions. The use of MMF is associated with a reduction in the incidence of death with a functioning graft in cadaveric renal transplantation. These results verify previous analyses.",
keywords = "Azathioprine, Cadaveric renal transplantation, Death with function, Immunosuppression, Mycophenolate mofetil",
author = "Schnitzler, {Mark A.} and Craig, {Karen E.} and Hardinger, {Karen E.} and Lowell, {Jeffrey A.} and Daniel Brennan",
year = "2003",
month = "6",
day = "1",
doi = "10.1093/ndt/gfg082",
language = "English (US)",
volume = "18",
pages = "1197--1200",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation

AU - Schnitzler, Mark A.

AU - Craig, Karen E.

AU - Hardinger, Karen E.

AU - Lowell, Jeffrey A.

AU - Brennan, Daniel

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Background. A previous study has argued that mycophenolate mofetil (MMF) is associated with a reduced incidence of death with function when compared to azathioprine (AZA) in cadaveric renal transplantation. This study was designed to verify this result because methodological issues bring these findings into question. Methods. The data used in this study was derived from records of renal transplants performed in 1995 and 1996 as recorded in the UNOS Scientific Renal Transplant Registry and supplied by the United States Renal Data System (USRDS). Univariate and multivariate survival analysis was used to compare rates of death with function. Covariate characteristics of the donor, recipient, procedures, early outcomes and the transplant centre were considered. Results. 12 251 recipients of cadaveric renal transplants were identified as having received either MMF or AZA, but not both. The relative risk of death with function calculated by the Kaplan-Meier method was 21% less for MMF patients (P = 0.005). MMF had from 21% (P = 0.008) to 24% (P = 0.001) reductions in relative risk by multivariate methods. Conclusions. The use of MMF is associated with a reduction in the incidence of death with a functioning graft in cadaveric renal transplantation. These results verify previous analyses.

AB - Background. A previous study has argued that mycophenolate mofetil (MMF) is associated with a reduced incidence of death with function when compared to azathioprine (AZA) in cadaveric renal transplantation. This study was designed to verify this result because methodological issues bring these findings into question. Methods. The data used in this study was derived from records of renal transplants performed in 1995 and 1996 as recorded in the UNOS Scientific Renal Transplant Registry and supplied by the United States Renal Data System (USRDS). Univariate and multivariate survival analysis was used to compare rates of death with function. Covariate characteristics of the donor, recipient, procedures, early outcomes and the transplant centre were considered. Results. 12 251 recipients of cadaveric renal transplants were identified as having received either MMF or AZA, but not both. The relative risk of death with function calculated by the Kaplan-Meier method was 21% less for MMF patients (P = 0.005). MMF had from 21% (P = 0.008) to 24% (P = 0.001) reductions in relative risk by multivariate methods. Conclusions. The use of MMF is associated with a reduction in the incidence of death with a functioning graft in cadaveric renal transplantation. These results verify previous analyses.

KW - Azathioprine

KW - Cadaveric renal transplantation

KW - Death with function

KW - Immunosuppression

KW - Mycophenolate mofetil

UR - http://www.scopus.com/inward/record.url?scp=0038346035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038346035&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfg082

DO - 10.1093/ndt/gfg082

M3 - Article

VL - 18

SP - 1197

EP - 1200

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 6

ER -